423 related articles for article (PubMed ID: 34044777)
1. Favipiravir for the treatment of patients with COVID-19: a systematic review and meta-analysis.
Manabe T; Kambayashi D; Akatsu H; Kudo K
BMC Infect Dis; 2021 May; 21(1):489. PubMed ID: 34044777
[TBL] [Abstract][Full Text] [Related]
2. Early antiviral treatment in outpatients with COVID-19 (FLARE): a structured summary of a study protocol for a randomised controlled trial.
Brown LK; Freemantle N; Breuer J; Dehbi HM; Chowdhury K; Jones G; Ikeji F; Ndoutoumou A; Santhirakumar K; Longley N; Checkley AM; Standing JF; Lowe DM
Trials; 2021 Mar; 22(1):193. PubMed ID: 33685502
[TBL] [Abstract][Full Text] [Related]
3. A Trial of Favipiravir and Hydroxychloroquine combination in Adults Hospitalized with moderate and severe Covid-19: A structured summary of a study protocol for a randomised controlled trial.
Bosaeed M; Mahmoud E; Hussein M; Alharbi A; Alsaedy A; Alothman A; Aljeraisy M; Alqahtani H; Nashabat M; Almutairi B; Almaghaslah M; Aldibasi O; AlJohani S; Bouchama A; Arabi Y; Alaskar A
Trials; 2020 Oct; 21(1):904. PubMed ID: 33129363
[TBL] [Abstract][Full Text] [Related]
4. The efficacy and safety of Favipiravir in treatment of COVID-19: a systematic review and meta-analysis of clinical trials.
Hassanipour S; Arab-Zozani M; Amani B; Heidarzad F; Fathalipour M; Martinez-de-Hoyo R
Sci Rep; 2021 May; 11(1):11022. PubMed ID: 34040117
[TBL] [Abstract][Full Text] [Related]
5. The Mechanism and Clinical Outcome of patients with Corona Virus Disease 2019 Whose Nucleic Acid Test has changed from negative to positive, and the therapeutic efficacy of Favipiravir: A structured summary of a study protocol for a randomised controlled trial.
Li J; Zhang C; Wu Z; Wang G; Zhao H
Trials; 2020 Jun; 21(1):488. PubMed ID: 32503657
[TBL] [Abstract][Full Text] [Related]
6. An adaptive randomised placebo controlled phase II trial of antivirals for COVID-19 infection (VIRCO): A structured summary of a study protocol for a randomised controlled trial.
McMahon JH; Lau JSY; Roney J; Rogers BA; Trubiano J; Sasadeusz J; Molton JS; Gardiner B; Lee SJ; Hoy JF; Cheng A; Peleg AY
Trials; 2020 Oct; 21(1):847. PubMed ID: 33050947
[TBL] [Abstract][Full Text] [Related]
7. Favipiravir versus other antiviral or standard of care for COVID-19 treatment: a rapid systematic review and meta-analysis.
Shrestha DB; Budhathoki P; Khadka S; Shah PB; Pokharel N; Rashmi P
Virol J; 2020 Sep; 17(1):141. PubMed ID: 32972430
[TBL] [Abstract][Full Text] [Related]
8. Glasgow Early Treatment Arm Favirpiravir (GETAFIX) for adults with early stage COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Hanna CR; Blyth KG; Burley G; Carmichael S; Evans C; Hinsley S; Khadra I; Khoo S; Lewsley LA; Jones RR; Sharma R; Taladriz-Sender A; Thomson EC; Scott JT
Trials; 2020 Nov; 21(1):935. PubMed ID: 33213530
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of favipiravir in COVID-19: a live systematic review.
Özlüşen B; Kozan Ş; Akcan RE; Kalender M; Yaprak D; Peltek İB; Keske Ş; Gönen M; Ergönül Ö
Eur J Clin Microbiol Infect Dis; 2021 Dec; 40(12):2575-2583. PubMed ID: 34347191
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial.
Udwadia ZF; Singh P; Barkate H; Patil S; Rangwala S; Pendse A; Kadam J; Wu W; Caracta CF; Tandon M
Int J Infect Dis; 2021 Feb; 103():62-71. PubMed ID: 33212256
[TBL] [Abstract][Full Text] [Related]
11. A Prospective, Randomized, Open-Label Trial of Early versus Late Favipiravir Therapy in Hospitalized Patients with COVID-19.
Doi Y; Hibino M; Hase R; Yamamoto M; Kasamatsu Y; Hirose M; Mutoh Y; Homma Y; Terada M; Ogawa T; Kashizaki F; Yokoyama T; Koba H; Kasahara H; Yokota K; Kato H; Yoshida J; Kita T; Kato Y; Kamio T; Kodama N; Uchida Y; Ikeda N; Shinoda M; Nakagawa A; Nakatsumi H; Horiguchi T; Iwata M; Matsuyama A; Banno S; Koseki T; Teramachi M; Miyata M; Tajima S; Maeki T; Nakayama E; Taniguchi S; Lim CK; Saijo M; Imai T; Yoshida H; Kabata D; Shintani A; Yuzawa Y; Kondo M
Antimicrob Agents Chemother; 2020 Nov; 64(12):. PubMed ID: 32958718
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of favipiravir versus hydroxychloroquine in management of COVID-19: A randomised controlled trial.
Dabbous HM; El-Sayed MH; El Assal G; Elghazaly H; Ebeid FFS; Sherief AF; Elgaafary M; Fawzy E; Hassany SM; Riad AR; TagelDin MA
Sci Rep; 2021 Mar; 11(1):7282. PubMed ID: 33790308
[TBL] [Abstract][Full Text] [Related]
13. Tocilizumab combined with favipiravir in the treatment of COVID-19: A multicenter trial in a small sample size.
Zhao H; Zhu Q; Zhang C; Li J; Wei M; Qin Y; Chen G; Wang K; Yu J; Wu Z; Chen X; Wang G
Biomed Pharmacother; 2021 Jan; 133():110825. PubMed ID: 33378989
[TBL] [Abstract][Full Text] [Related]
14. Nasopharyngeal SARS-CoV-2 Viral Load Response among COVID-19 Patients Receiving Favipiravir.
Manosuthi W; Jeungsmarn S; Okada P; Suwanvattana P; Wongboot W; Thawornwan U; Charoenpong L; Wiboonchutikul S; Uttayamakul S; Pongpirul WA; Wachirapan A; Warachit P
Jpn J Infect Dis; 2021 Sep; 74(5):416-420. PubMed ID: 33518623
[TBL] [Abstract][Full Text] [Related]
15. Clinical antiviral efficacy of favipiravir in early COVID-19 (PLATCOV): an open-label, randomised, controlled, adaptive platform trial.
Luvira V; Schilling WHK; Jittamala P; Watson JA; Boyd S; Siripoon T; Ngamprasertchai T; Almeida PJ; Ekkapongpisit M; Cruz C; Callery JJ; Singh S; Tuntipaiboontana R; Kruabkontho V; Ngernseng T; Tubprasert J; Abdad MY; Keayarsa S; Madmanee W; Aguiar RS; Santos FM; Hanboonkunupakarn P; Hanboonkunupakarn B; Poovorawan K; Imwong M; Taylor WRJ; Chotivanich V; Chotivanich K; Pukrittayakamee S; Dondorp AM; Day NPJ; Teixeira MM; Piyaphanee W; Phumratanaprapin W; White NJ;
BMC Infect Dis; 2024 Jan; 24(1):89. PubMed ID: 38225598
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the efficacy and safety of favipiravir and interferon compared to lopinavir/ritonavir and interferon in moderately ill patients with COVID-19: a structured summary of a study protocol for a randomized controlled trial.
Hassaniazad M; Bazram A; Hassanipour S; Fathalipour M
Trials; 2020 Oct; 21(1):886. PubMed ID: 33109246
[TBL] [Abstract][Full Text] [Related]
17. Systematic review and meta-analysis of effectiveness and safety of favipiravir in the management of novel coronavirus (COVID-19) patients.
Prakash A; Singh H; Kaur H; Semwal A; Sarma P; Bhattacharyya A; Dhibar DP; Medhi B
Indian J Pharmacol; 2020; 52(5):414-421. PubMed ID: 33283773
[TBL] [Abstract][Full Text] [Related]
18. Systematic Review on Repurposing Use of Favipiravir Against SARS-CoV-2.
Nasir M; Perveen RA; Saha SK; Talha KA; Selina F; Islam MA
Mymensingh Med J; 2020 Jul; 29(3):747-754. PubMed ID: 32844821
[TBL] [Abstract][Full Text] [Related]
19. Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea.
Sissoko D; Laouenan C; Folkesson E; M'Lebing AB; Beavogui AH; Baize S; Camara AM; Maes P; Shepherd S; Danel C; Carazo S; Conde MN; Gala JL; Colin G; Savini H; Bore JA; Le Marcis F; Koundouno FR; Petitjean F; Lamah MC; Diederich S; Tounkara A; Poelart G; Berbain E; Dindart JM; Duraffour S; Lefevre A; Leno T; Peyrouset O; Irenge L; Bangoura N; Palich R; Hinzmann J; Kraus A; Barry TS; Berette S; Bongono A; Camara MS; Chanfreau Munoz V; Doumbouya L; Souley Harouna ; Kighoma PM; Koundouno FR; Réné Lolamou ; Loua CM; Massala V; Moumouni K; Provost C; Samake N; Sekou C; Soumah A; Arnould I; Komano MS; Gustin L; Berutto C; Camara D; Camara FS; Colpaert J; Delamou L; Jansson L; Kourouma E; Loua M; Malme K; Manfrin E; Maomou A; Milinouno A; Ombelet S; Sidiboun AY; Verreckt I; Yombouno P; Bocquin A; Carbonnelle C; Carmoi T; Frange P; Mely S; Nguyen VK; Pannetier D; Taburet AM; Treluyer JM; Kolie J; Moh R; Gonzalez MC; Kuisma E; Liedigk B; Ngabo D; Rudolf M; Thom R; Kerber R; Gabriel M; Di Caro A; Wölfel R; Badir J; Bentahir M; Deccache Y; Dumont C; Durant JF; El Bakkouri K; Gasasira Uwamahoro M; Smits B; Toufik N; Van Cauwenberghe S; Ezzedine K; D'Ortenzio E; Pizarro L; Etienne A; Guedj J; Fizet A; Barte de Sainte Fare E; Murgue B; Tran-Minh T; Rapp C; Piguet P; Poncin M; Draguez B; Allaford Duverger T; Barbe S; Baret G; Defourny I; Carroll M; Raoul H; Augier A; Eholie SP; Yazdanpanah Y; Levy-Marchal C; Antierrens A; Van Herp M; Günther S; de Lamballerie X; Keïta S; Mentre F; Anglaret X; Malvy D;
PLoS Med; 2016 Mar; 13(3):e1001967. PubMed ID: 26930627
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Favipiravir for the Treatment of COVID-19 Outpatients: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
Cheema HA; Ali A; Ali M; Shahid A; Ghafoor MS; Ur Rehman ME; Sah R; Sahra S; Ahmad S
Am J Ther; 2024 May-Jun 01; 31(3):e328-e331. PubMed ID: 37647511
[No Abstract] [Full Text] [Related]
[Next] [New Search]
